CLINICAL TRIALS PROFILE FOR BERINERT

All Clinical Trials for BERINERT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	Clinical trial center Rhine-Main	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	CSL Behring	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	Institut für Medizinische Virologie JWG-University hospital	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	PharmaPart	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	University of Milan	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	ZKI Kindergerinnungslabor	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.
NCT00748202 ↗	Berinert P Study of Subcutaneous Versus Intravenous Administration	Completed	Johann Wolfgang Goethe University Hospital	Phase 3	2008-09-01	The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.

Clinical Trial Conditions for BERINERT

Condition Name

Condition Name for BERINERT
Intervention	Trials
Hereditary Angioedema	3
End Stage Renal Disease	2
Ischemic Reperfusion Injury	1
Kidney Failure	1

Condition MeSH

Condition MeSH for BERINERT
Intervention	Trials
Angioedemas, Hereditary	4
Angioedema	4
Kidney Failure, Chronic	2
Kidney Diseases	2

Clinical Trial Locations for BERINERT

Trials by Country

Trials by Country for BERINERT
Location	Trials
United States	4
Germany	2
Russian Federation	1

Trials by US State

Trials by US State for BERINERT
Location	Trials
California	3
New York	1

Clinical Trial Progress for BERINERT

Clinical Trial Phase

Clinical Trial Phase for BERINERT
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for BERINERT
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for BERINERT

Sponsor Name

Sponsor Name for BERINERT
Sponsor	Trials
CSL Behring	3
Cedars-Sinai Medical Center	2
ZKI Kindergerinnungslabor	1

Sponsor Type

Sponsor Type for BERINERT
Sponsor	Trials
Other	13
Industry	5